|
 |
UltaneThis page contains recent news articles, when available, and an overview of Ultane but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Ultane (when available) Sevoflurane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery Mechanism Of Action: Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. Also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Sevoflurane also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor and the glycine receptor. News Articles on Sevoflurane Why did Zenande have to die? - Dec 24, 2009 The anaesthetist is Dr Marius Gouws, who is using ultane oxygen and air, plus Macaine, a local anaesthetic. Zenande keeps sneezing and kicking, ... Noseweek Abbott Shares May Be 'Close To Bottoming' - Sep 26, 2005 ...last Friday it won a patent dispute regarding the generic form of Ultane, ... the ODAC Xinlay rejection and the Ultane ruling," said Morgan Stanley. ... Forbes Abbott Reports 17.5 Percent Sales Increase in the Second Quarter - Jul 13, 2005 HUMIRA $353 47.7 $250 122.5 $603 71.5 Depakote $456 7.2 $27 16.3 $483 7.7 Kaletra $190 0.9 $284 19.3(b) $474 11.2 Ultane/Sevorane $160 23.4 $263 13.2(c) ... RedOrbit Economic and safety considerations of fast-acting inhaled anesthetics.... - Oct 1, 2007 Thus, on a per MAC/hour basis, branded sevoflurane (Ultane) is found to be ... Branded sevoflurane (Ultane) has been safely used in millions of procedures ... $4.95 - Formulary - ECNext Analyst fears generics could cut into Abbott profits - Mar 28, 2005 On the Ultane front, Reicin noted agreements are in place between Baxter and Abbott that protect Abbott from any generic competition until December. ... $2.95 - Chicago Sun-Times - NewsBank Abbott Reports 16.1 Percent Sales Growth in Fourth Quarter. - Jan 23, 2008 20.5 Kaletra $153 11.1 $218 37.4(b) $371 25.2 Biaxin (clarithromycin) $16 (71.7) $184 2.3(c) $200 (15.2) Ultane/Sevorane $50 (13.6) $150 9.7(d) $200 2.8 ... Free with registration - PR Newswire - AccessMyLibrary.com Abbott Reports Strong Fourth-Quarter Results and Record Operating … - Jan 24, 2007 ...$179 (4.7)(c) $235 (16.4) Ultane/Sevorane $58 (36.4) $137 (3.8)(d) $195 ... (clarithromycin) $151 (50.5) $665 (12.5)(b) $816 (23.4) Ultane/Sevorane $260 ... Free with registration - PR Newswire - AccessMyLibrary.com Abbott Reports Record Sales, Earnings and Cash Flow in 2005 - Jan 25, 2006 Kaletra $124 10.4 $148 10.4 $272 10.4 Ultane/Sevorane $91 14.7 $142 7.8 (b) ... $1005 12.2 TriCor $927 18.9 --- --- $927 18.9 Ultane/Sevorane $336 16.0 ... RedOrbit Abbott Reports 15.0 Percent Sales Increase in the Third Quarter - Oct 19, 2005 8.9 $154 21.9 $260 16.2 TriCor $225 8.1 --- --- $225 8.1 Ultane/Sevorane $86 ... $437 20.2(b) $733 12.9 Ultane/Sevorane $246 16.6 $395 12.4(c) $641 13.9 ... RedOrbit Abbott Reports Strong Third-Quarter Results, Announces $2.5 Billion … - Oct 18, 2006 ...$266 18.3 Ultane/Sevorane $56 (35.2) $133 1.2(c) $189 (13.2) Synthroid $132 9.3 $17 11.9 $149 9.6 Biaxin (clarithromycin) $16 (61.6) $122 (10.5)(d) $138 ... $4.95 - PR Newswire - ECNext Abbott Reports 15.8 Percent Sales Growth in Second Quarter. - Jul 18, 2007 ...(b) $315 18.9 TriCor $302 20.6 --- --- $302 20.6 Ultane/Sevorane $53 (18.5) ... $394 (11.0) Ultane/Sevorane $101 (31.2) $270 0.8 (d) $371 (10.6) Niaspan ... $4.95 - PR Newswire - ECNext Abbott Reports 15.5 Percent Sales Increase in the Fourth Quarter;... - Jan 18, 2005 Kaletra $398 3.9 $498 35.0(b) $896 19.2 HUMIRA $555 125.6 $297 n/m $852 204.3 TriCor $779 37.6 --- --- $779 37.6 Ultane/Sevorane $290 12.7 $484 15.9(c) ... $4.95 - PR Newswire - ECNext Loislaw Federal District Court Opinions - ABBOTT LABORATORIES v. … - Sep 26, 2005 Abbott first began to sell sevoflurane, a product it labeled as Ultane, in glass bottles beginning in 1995. (Id. at 860.) In January 1995, the food and drug ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Loislaw Federal District Court Opinions - ABBOTT LABORATORIES v. … - Sep 22, 2005 Abbott first began to sell sevoflurane, a product it labeled as Ultane, in glass bottles beginning in 1995. (Id. at 860.) In January 1995, the food and drug ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Abbott appeal on inhaler fails - Nov 10, 2006 Abbott Laboratories lost a bid to block sales of Baxter International Inc.'s generic version of the inhaled anesthetic Ultane. The U.S. Court of Appeals for ... Pay-Per-View - Chicago Tribune - ProQuest Archiver Painkillers' Surprising Legacy Is More Pain - Jun 23, 2008 ...volatile anesthetics, such as isoflurane, were the ones that stimulated TPRA1, while non-pungent drugs, such as sevoflurane (Ultane), had no effect. ... MedPage Today Drug Stocks Dull Even With FDA-Related News - Mar 21, 2005 ...people ) for a generic version of general anesthetic Ultane further clouds the near-term view. Morgan Stanley maintained a $52 price target for Abbott. ... Forbes Baxter moves ahead with drug despite fight - Jan 2, 2006 In September, a US District Court judge ruled Baxter's sevoflurane doesn't infringe a patent on Abbott's inhaled anesthetic agent, Ultane. ... $2.95 - Chicago Sun-Times - NewsBank Abbott Labs May Outperform Market By 15% In Near Term - Oct 4, 2005 Food and Drug Administration panel review of Xinlay and Baxter International (nyse: BAX - news - people )'s patent dispute win for generic Ultane. ... Forbes Le monde agricole à l'honneur - Sep 19, 2008 Concours départemental Prim'holstein : la vache Ultane au GAEC De Hurtenent remporte le grand championnat en battant la championne de Terres en Fête 2008 ... La Voix du Nord Abbott Labs Still Has 'Considerable' Upside Potential - Nov 28, 2005 Its disappointments include the Food and Drug Administration's rejection of Xinlay and a loss in the Ultane case to Baxter International (nyse: BAX - news ... Forbes Coming Out of Anesthesia Not Mirror Image of Going Under - Jan 11, 2008 ...so he and colleagues began investigating their role in anesthesia, using the inhaled anesthetics isoflurane (Forane) and sevoflurane (Ultane). ... MedPage Today Abbott Reports 15.5 Percent Sales Growth in First Quarter. - Apr 18, 2007 Kaletra $117 (2.4) $183 14.5 (b) $300 7.2 Biaxin (clarithromycin) $7 (85.2) $217 9.5 (c) $224 (9.9) TriCor $223 8.7 --- --- $223 8.7 Ultane/Sevorane $48 ... Free with registration - PR Newswire - AccessMyLibrary.com Abbott Reports First Quarter Results Led by Strong Medical Products … - Apr 19, 2006 ...(clarithromycin) $51 (55.2) $198 (17.3)(c) $249 (29.5) Depakote $229 12.0 $17 39.0 $246 13.5 Ultane/Sevorane $82 9.4 $125 2.5 (d) $207 5.2 TriCor $205 ... Free with registration - PR Newswire - AccessMyLibrary.com Premier Enhances Analytical Tools to Maximize Savings from Pharmacy … - Dec 20, 2007 With the addition of Abbott's Ultane and Baxter's IAG programs, Premier has 15 pharmacy performance programs available to its members. ... Free with registration - Business Wire - AccessMyLibrary.com Event Brief of Q3 2006 Abbott Laboratories Earnings Conference Call -... - Oct 1, 2006 Sevofluorane market share and volumes have remained steady as commercial team actively promotes Ultane. 2. Maintains strong relationship and leadership ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Q1 2006 Abbott Laboratories Earnings Conference Call - Part 2. - Apr 19, 2006 One on Ultane in the US Obviously we're waiting for a Baxter launch. I'm wondering if you can go through kind of the preparations that Abbott's making ahead ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Article: Analyst fears generics could cut into Abbott profits -... - Mar 28, 2005 ...concerns about potential generic competition facing its inhaled anesthetic agent Ultane, or Sevoflurane, from Deerfield-based Baxter International Inc. ... Pay-Per-View - Chicago Sun-Times - HighBeam Research Top 200 drugs used in hospitals in 2006.(Table) - Apr 16, 2007 Taxotere 286624362.00 4.26 26 Ultane 284418649.68 2.70 27 Cancidas 275150690.26 -0.74 28 Thrombin-JMI 254922999.49 10.24 29 Sodium Chloride 252097230.90 ... $4.95 - Drug Topics - ECNext Event Brief of Q3 2006 Abbott Laboratories Earnings Conference Call -... - Oct 18, 2006 Sevofluorane market share and volumes have remained steady as commercial team actively promotes Ultane. 2. Maintains strong relationship and leadership ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Abbott profits slide on cost cutting; shares rise: Humira helps drive... - Oct 20, 2005 Citing Abbott's inhaled anesthetic Ultane, which is expected to face generic competition from Deerfield-based Baxter International next year, ... Pay-Per-View - Chicago Sun-Times - HighBeam Research Loislaw Federal District Court Opinions - LABORATORIES v. BAXTER … - Sep 28, 2007 Sevoflurane, which is found in Abbott's Ultane TM product, is used to induce and maintain general anesthesia in adult and pediatric Page 2 patients. ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw United States top 200 brand and generic drugs used in hospitals in … - Jun 19, 2006 354711452.46 -7.05 53 Lexapro 337722763.25 27.62 54 Integrilin 334507341.61 -3.26 55 Cancidas 323310648.21 24.84 56 Ultane 316228796.18 15.88 57 Abilify ... $20.00 - Drug Topics - Alacra Store Abbott Labs' 2Q Profit Rises on Sales - Jul 13, 2005 Other drugs that saw sharp revenue growth included inhaled anesthetic agent Ultane, which increased 17.7 percent to $226 million, and cholesterol-lowering ... RedOrbit Anesthesia: Numbed by choices? - Dec 1, 2006 It does have many widely used descendants, including enflurane (Ethrane) and sevoflurane (Ultane). Most of the drugs used in general anesthesia are ... Pay-Per-View - Harvard Health Letter - Factiva, from Dow Jones Abbott Reports First Quarter Results - Apr 12, 2005 ...led by strong contributions from major branded products, including HUMIRA, Kaletra, Biaxin, Omnicef, Ultane/Sevorane, Depakote and Mobic. ... WebProNews Baxter Launches First Sevoflurane in China and Announces Phased … - Dec 12, 2005 Baxter's sevoflurane is chemically and therapeutically equivalent to Ultane(R) (Abbott Laboratories). The addition of sevoflurane distinguishes Baxter as ... biotech-intelligence.com Lowe closes agency; Chairman blames loss of Xolair - Jun 2, 2005 Professional work for Abbott's Ultane and Hospira may go to Pace, as well. "We're still in discussions with Abbott with trying to get those over to Pace," ... Medical Marketing & Media - Medical Marketing and Media Amgen Buying Abgenix for $2.2B and MedImmune and Biota Announce … - Dec 15, 2005 Abbott sells the anesthesia -- which is delivered using a vaporizer machine -- under the Ultane brand. Baxter has had FDA approval to sell its sevoflurane ... Free with registration - M2 Presswire - AccessMyLibrary.com Event Brief of Q1 2005 Abbott Laboratories Earnings Conference Call -... - Apr 12, 2005 US pharmaceutical business, which delivered nearly 20% growth led by strength in a number of products, including HUMIRA, Kaletra, Ultane, Depakote, Mobic, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Fitch Affirms Abbott Laboratories 'AA-'; Outlook Stable. - Dec 22, 2005 Potential patent exclusivity losses in the intermediate term include an extended-release formulation of Biaxin, Ultane/sevoflurane, and Depakote. ... Free with registration - Business Wire - AccessMyLibrary.com Stocks to Follow and Alerts for Monday, Dec 12, 2005 SKPI ECPN and … - Dec 12, 2005 Baxter's sevoflurane is chemically and therapeutically equivalent to Ultane (Abbott Laboratories). The addition of sevoflurane distinguishes Baxter as the ... Free with registration - M2 Presswire - AccessMyLibrary.com Baxter launches sevoflurane in China.(Baxter Healthcare Corp.)(Brief ... - Dec 19, 2005 Baxter says its sevoflurane is chemically and therapeutically equivalent to Abbott Laboratories' Ultane. The addition of sevoflurane distinguishes Baxter as ... $4.95 - Pharma Marketletter - ECNext Zacks Brokerage Buy List: Abbott, Automatic Data Processing, Cisco... - Sep 2, 2005 Sales for Abbott's Pharmaceutical Products Group advanced 18%, thanks to strong performances from HUMIRA, Ultane(R)/Sevorane, TriCor, Omnicef, and Mobic. ... $4.95 - Business Wire - ECNext Press Release: Baxter Launches First Sevoflurane in China and … - Dec 12, 2005 Baxter's sevoflurane is chemically and therapeutically equivalent to Ultane(R) (Abbott Laboratories). The addition of sevoflurane distinguishes Baxter as ... Pay-Per-View - PR Newswire - HighBeam Research Brand Names/Synonyms: Ultane is also known by the following brand names and/or synonymsBax 3084; CHEMBANK2842; MR6S4; Sevofluran; Sevoflurane; Sevoflurane [Usan:Ban:Inn:Jan]; Sevoflurano [Inn-Spanish]; Sevofluranum [Inn-Latin]; Sevorane; Ultane; [Inn-Latin] Drug Category: Ultane is categorized under the following by the FDA: Anesthetics; General Anesthetics; ATC:N01AB08 Dosage Forms: LIQUID Absorption: Rapidly absorbed into the circulation via the lungs Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |